Tirzepatide significantly simplifies type 2 diabetes treatment regimens, outperforming conventional GLP-1 RAs

Managing type 2 diabetes mellitus (T2DM) often involves complex polypharmacy and intricate insulin regimens, significantly increasing patient treatment burden and potentially reducing adherence. This complexity highlights a critical need for therapeutic strategies that can simplify treatment while maintaining or improving metabolic control. Tirzepatide, a novel dual GLP-1R/GIPR agonist, has demonstrated potent glucose-lowering and weight-reducing effects in clinical trials. However, its real-world impact on simplifying medication schedules and insulin requirements, a key aspect of patient quality of life, remained underexplored.

This retrospective real-world study compared Tirzepatide (TZP) against conventional GLP-1 receptor agonists (GLP-1 RAs) over a 12-month period. The study included a total of 318 patients (TZP, n = 153; GLP-1 RAs, n = 165) with type 2 diabetes mellitus. The primary outcome was defined as treatment simplification, which encompassed a reduction in the total number of antidiabetic medications, fewer insulin injections, or a ≥50% reduction in the total daily insulin dose. To account for potential confounding factors inherent in real-world data, propensity score overlap weighting and multiple imputations were rigorously applied.

Tirzepatide demonstrated a significantly higher likelihood of achieving treatment simplification compared to conventional GLP-1 RAs. Specifically, 55% of patients on Tirzepatide experienced treatment simplification, in stark contrast to only 25% of those on conventional GLP-1 RAs. This difference corresponds to a substantial absolute risk difference of 30%. Statistical analysis revealed that Tirzepatide was 3.69 times more likely to lead to treatment simplification (odds ratio: 3.69, 95% confidence interval: 2.21-6.16; P < 0.001).